0
Clinical Investigations: ASTHMA |

Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast*

Kenji Minoguchi, MD, PhD; Yasurou Kohno, MD, PhD; Hideko Minoguchi, MD; Norio Kihara, MD, PhD; Yasuyuki Sano, MD, PhD; Hajime Yasuhara, MD, PhD; Mitsuru Adachi, MD, PhD
Author and Funding Information

*From the First Department of Internal Medicine (Drs. K. Minoguchi, Kohno, and Adachi), Showa University, School of Medicine; the Department of Respirology (Drs. H. Minoguchi and Kihara), Kihara Hospital; the Department of Allergy and Respiratory Medicine (Dr. Sano), Doai Memorial Hospital; and the Second Department of Pharmacology (Dr. Yasuhara), Showa University, School of Medicine, Tokyo, Japan.

Correspondence to: Kenji Minoguchi, MD, PhD, the First Department of Internal Medicine, Showa University, School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan



Chest. 2002;121(3):732-738. doi:10.1378/chest.121.3.732
Text Size: A A A
Published online

Objective: Leukotrienes (LTs) are involved in airway eosinophilic inflammation in patients with asthma. We examined the effects of a cysteinyl LT 1-receptor antagonist, montelukast, on sputum eosinophil levels, and the correlation between sputum eosinophils and bronchodilatation in patients with asthma.

Design: Double-blind, randomized, crossover study.

Setting: University hospital and private hospital.

Patients: Twenty-nine patients with mild-to-moderate asthma.

Interventions: Montelukast, 10 mg, and placebo tablet, once daily, each for 4 weeks.

Measurements: Sputum eosinophils analyzed using hypertonic saline solution-induced sputum and airway hyperresponsiveness to histamine were evaluated before and after treatment. In addition, morning and evening peak expiratory flow (PEF), asthma symptoms, and peripheral blood eosinophil levels were assessed.

Results: The percentage of eosinophils in sputum decreased from 24.6 ± 12.3% at baseline to 15.1 ± 11.8% after montelukast treatment, for a change of − 9.5 ± 12.7% (n = 20). During placebo administration, the percentage of eosinophils fell from 21.3 ± 12.1% to 21.0 ± 11.5%, resulting in a decrease of − 0.3 ± 10.8% (n = 20). There was a statistically significant difference in the change in sputum eosinophil levels between these two periods (p < 0.005). The number of peripheral blood eosinophils also significantly decreased after montelukast treatment (314.1 ± 237.6/mL) compared with placebo (413.1 ± 232.1/mL; p < 0.005, n = 21). Although morning and evening PEF values were significantly improved from baseline after montelukast treatment (p < 0.01, n = 20), asthma symptoms and airway responsiveness to histamine were not significantly altered. Furthermore, there was no significant correlation between the decrease in sputum eosinophils and the increase in PEF.

Conclusion: These results suggest that montelukast has anti-inflammatory effects on the airway in patients with asthma, and that its bronchodilatory effect is not solely dependent on a decrease in airway eosinophilia.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543